Reported 12 months ago
British drugmaker GSK has purchased partner CureVac's share in their joint efforts on developing influenza and COVID-19 vaccines. GSK will gain control of CureVac's leading experimental vaccines for seasonal flu and bird flu by paying 400 million euros upfront and up to 1.05 billion euros based on achievements. CureVac will cut 30% of its workforce to focus on mRNA-based cancer therapies, while GSK's cash infusion will extend funding until 2028.
Source: YAHOO